Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Aveni Foundation
Var2 Pharmaceuticals
Taproot Health
Ipsen
Eastern Cooperative Oncology Group
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Novartis
Celldex Therapeutics
Rutgers, The State University of New Jersey
Valerio Therapeutics
Valerio Therapeutics
University of South Florida
INSYS Therapeutics Inc
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center